Familial hypercholesterolaemia (FH) is an autosomal codominant disorder characterised by high levels of LDL cholesterol and a high incidence of coronary artery disease. Our aims were to track the low density lipoprotein receptor (LDLR) gene in individual families with phenotypic FH and to identify and characterise any mutations of the LDLR gene that may be common in the west of Scotland FH population using single strand conformational polymorphism analysis (SSCP). Patient samples consisted of 80 heterozygous probands with FH, 200 subjects who were related to the probands, and a further 50 normal, unrelated control subjects. Tracking of the LDLR gene was accomplished by amplification of a 19 allele tetranucleotide microsatellite that is tightly linked to the LDLR gene locus. Primers specific for exon 4 of the LDLR gene were used to amplify genomic DNA and used for SSCP analysis. Any PCR products with different migration patterns as assessed by SSCP were then sequenced directly. In addition to identifying probands with a common mutation, family members were screened using a forced restriction site assay and analysed using microplate array diagonal gel electrophoresis (MADGE). Microsatellite D19S394 analysis was informative in 20 of 23 families studied. In these families there was no inconsistency with segregation of the FH phenotype with the LDLR locus. Of the FH probands, 15/80 had a mutant allele as assessed by SSCP using three pairs of primers covering the whole of exon 4 of the LDLR gene. Direct DNA sequencing showed that 7/15 of the probands had a C163Y mutation. Using a PCR induced restriction site assay for the enzyme RsaI and MADGE, it was determined that the C163Y mutation cosegregated with the FH phenotype in family members of the FH probands. This mutant allele was not present in any of the control subjects. Microsatellite analysis has proven useful in tracking the LDLR gene and could be used in conjunction with LDL cholesterol levels to diagnose FH, especially in children and young adults where phenotypic diagnosis can be difficult. The large interpersonal variability in phenotypic expression of FH could be explained by the underlying mutation that is present in the affected subjects,7-9 though other genetic influences such as apoE polymorphism or the presence of a missense mutation in the LDLR binding region of apoB may also play an important role. 10-12 Previous studies have shown that within geographically or culturally isolated populations or where a large population is related by descent, the frequency of certain mutations is increased.'3 14 This is illustrated by the French Canadian population where a 10 kb deletion at the 5' end of the LDLR gene accounts for 60% of the FH population and, even more strikingly, 100% of the Lebanese FH cases studied had a simple base pair substitution which results in the formation of a stop codon and ultimately a truncated form of the LDL receptor with less than 2% LDLR activity." 1
Abstract
Familial hypercholesterolaemia (FH) is an autosomal codominant disorder characterised by high levels of LDL cholesterol and a high incidence of coronary artery disease. Our aims were to track the low density lipoprotein receptor (LDLR) gene in individual families with phenotypic FH and to identify and characterise any mutations of the LDLR gene that may be common in the west of Scotland FH population using single strand conformational polymorphism analysis (SSCP). Patient samples consisted of 80 heterozygous probands with FH, 200 subjects who were related to the probands, and a further 50 normal, unrelated control subjects. Tracking of the LDLR gene was accomplished by amplification of a 19 allele tetranucleotide microsatellite that is tightly linked to the LDLR gene locus. Primers specific for exon 4 of the LDLR gene were used to amplify genomic DNA and used for SSCP analysis. Any PCR products with different migration patterns as assessed by SSCP were then sequenced directly. In addition to identifying probands with a common mutation, family members were screened using a forced restriction site assay and analysed using microplate array diagonal gel electrophoresis (MADGE). Microsatellite D19S394 analysis was informative in 20 of 23 families studied. In these families there was no inconsistency with segregation of the FH phenotype with the LDLR locus. Of the FH probands, 15/80 had a mutant allele as assessed by SSCP using three pairs of primers covering the whole of exon 4 of the LDLR gene. Direct DNA sequencing showed that 7/15 of the probands had a C163Y mutation. Using a PCR induced restriction site assay for the enzyme RsaI and MADGE, it was determined that the C163Y mutation cosegregated with the FH phenotype in family members of the FH probands. This mutant allele was not present in any of the control subjects. Microsatellite analysis has proven useful in tracking the LDLR gene and could be used in conjunction with LDL cholesterol levels to diagnose FH, especially in children and young adults where phenotypic diagnosis can be difficult. ( The large interpersonal variability in phenotypic expression of FH could be explained by the underlying mutation that is present in the affected subjects,7-9 though other genetic influences such as apoE polymorphism or the presence of a missense mutation in the LDLR binding region of apoB may also play an important role. 10-12 Previous studies have shown that within geographically or culturally isolated populations or where a large population is related by descent, the frequency of certain mutations is increased.'3 14 This is illustrated by the French Canadian population where a 10 kb deletion at the 5' end of the LDLR gene accounts for 60% of the FH population and, even more strikingly, 100% of the Lebanese FH cases studied had a simple base pair substitution which results in the formation of a stop codon and ultimately a truncated form of the LDL receptor with less than 2% LDLR activity." 1
The large size of the LDLR gene in conjunction with the numerous mutations so far characterised makes the detection of mutations in the LDLR gene difficult. A large number of mutations, such as large insertions and deletions, have been detected using restriction fragment length polymorphism (RFLP) analysis and Southern blotting.'7 A newer method, Identification of a common low density lipoprotein receptor mutation (C163Y) From three of the FH probands with the C163Y mutation, additional family members were available. These family members were subjected to direct sequencing to establish the presence or absence of the C 163Y mutation of the LDLR gene. From the first family studied, one of the sisters of the proband showed the presence of the C163Y mutation and had a raised cholesterol, whereas the remaining sibs did not have the mutation and had normal cholesterol levels (fig 2A) . In the second family, three relatives of the proband had the C163Y mutation and a raised cholesterol ( fig 2B) ; other family members tested for the mutation were negative for the C163Y mutation. In the Identification of a common low density lipoprotein receptor mutation (C163Y) in young children where it can be difficult to diagnose FH using clinical and biochemical data alone. SSCP is a relatively simple method which makes it a powerful tool for detecting mutations but can be rather time consuming, and this is complicated by the fact that direct sequencing of any mutant alleles detected by SSCP would be required. The assay for introducing the restriction site for RsaI would prove useful in mass screening for the C163Y mutation in the FH population. It has been reported that even though the UK FH population is heterogeneous in its ancestry, regional variation of certain mutations of the LDLR gene occurs.3 This has been shown in the FH population of the Manchester area where one such mutation (E80K) occurs in 10% of probands studied, with the mutation itself being widely distributed in the UK29 with a more typical prevalence of 1-2%. Recently it has been reported that in the south of England the mutation R329X also occurs in 10% of FH kindreds, though prevalence elsewhere is unknown. Cosegregation analysis in three of our families would suggest that the C163Y mutation described in the current study is responsible for the raised cholesterol observed in these seven FH probands. It has recently been shown that an allele of the microsatellite marker Dl 9S394 is in complete linkage disequilibrium with the LDLR mutation R329X. The authors have suggested that the use of this microsatellite marker would enable the rapid recognition of a possible common FH mutation within a group of FH patients from either a particular geographical location or a common ancestry.2' The marker is approximately 250 kb 5' to the LDL receptor gene suggesting that recombination would be relatively rare between the marker and the LDLR in a single generation. In our study, the marker was used to track the LDL receptor within individual families and alleviated the problems associated with using haplotype analysis and RFLPs. Of the seven patients with the C1 63Y mutation, five have one or more D19S394 227 bp alleles, compatible with the mutation having occurred relatively recently on a chromosome with this length, with this allelic association being maintained because of the small genetic distance, and thus the low rate of recombination, between the LDLR locus and the D19S394 locus. The remaining two probands have the microsatellite genotype 231/251 and 235/267, and this raises the possibility that the mutation may have occurred independently on at least two other chromosomes. We consider this to be unlikely since the G-4A change that creates the C 1 63Y mutation is not at a CpG mutational hot spot. Microsatellites are known to mutate primarily by the process of replication slippage,30 and this would result in the loss of allelic association. These possibilities could be examined in these patients by determining haplotypes using RFLPs within and flanking the LDL locus, but such data were not available for these subjects.
Among FH patients there is a great deal of variation in terms of the circulating lipid levels and the age of onset of coronary heart disease. 
